Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
6 search results for:

­Lurbinectedin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-09-2021 | WCLC 2021 | Conference coverage | Article

    No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

    The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

    Author:
    Shreeya Nanda
    Published in:
    IASLC 2021 World Conference on Lung Cancer; 8–14 September
  2. 17-06-2020 | FDA | News | Article
    approvalsWatch

    Lurbinectedin approved for US metastatic SCLC patients

    medwireNews : The US FDA has given accelerated approval for use of lurbinectedin in patients with metastatic small-cell lung cancer (SCLC) who have progressed during or after platinum-based chemotherapy.

    Author:
    Lynda Williams
  3. 12-02-2020 | Mesothelioma | News | Article

    Lurbinectedin confers clinical benefit in malignant pleural mesothelioma

    Lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma, say phase 2 trial investigators.

    Author:
    Hannah Kitt
    Published in:
    Ann Oncol 2020; doi:10.1016/j.annonc/2019/12/009
  4. 07-06-2019 | Small-cell lung cancer | News | Article

    Lurbinectedin shows potential for second-line SCLC treatment

    Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

    Published in:
    2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 Jun
  5. 09-10-2018 | Breast cancer | News | Article

    Lurbinectedin activity shown in metastatic breast cancer

    Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1 / 2 -mutated metastatic breast cancer, phase II study data show.

    Published in:
    J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6558
  6. 27-09-2017 | Small-cell lung cancer | ESMO 2017 | Article
    ESMO 2017

    Preliminary lurbinectedin results ‘remarkable’ for relapsed SCLC

    Lurbinectedin has potential for the treatment of patients with relapsed small-cell lung cancer as a single agent or in combination with another chemotherapy drug, suggests research reported at the ESMO 2017 Congress in Madrid, Spain.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.